Shares of biopharmaceutical company Inozyme Pharma (NASDAQ:INZY) are soaring higher today after it announced positive topline and safety data in presently ongoing Phase 1/2 trials of INZ-701.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The drug is being evaluated for the treatment of ENPP1 deficiency and ABCC6 deficiency (PXE) and demonstrated improved PPi (plasma pyrophosphate) levels as well as a favorable safety profile in patients.
Next, the company is aiming to begin a pivotal trial of the drug in pediatric patients with ENPP1 deficiency. Importantly, INZY expects cash and equivalents of $127.9 million for the period ending December 31, 2022. The cash position places the company comfortably well into Q4 2024.
Overall, Wall Street has a consensus price target of $20 on INZY, implying a more than massive 547% potential upside in the stock. That’s on top of the 69% gain in the share price over the past month.
Read full Disclosure
